APOE ε4 carriers may be particularly susceptible to low dream recall and future dementia given their higher global Aβ burden and DMN tau levels24,25 and the potential for APOE ε4 to influence the DMN via non-amyloid pathways.26 The gene discussed is MAPT; the disease is dementia.